- Home
- PRTG vs ABP Comparison
PRTG vs ABP Comparison
Compare PRTG & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- ABP
- Stock Information
- Founded
- PRTG 1973
- ABP 2004
- Country
- PRTG British Virgin Islands
- ABP United States
- Employees
- PRTG N/A
- ABP N/A
- Industry
- PRTG Oil & Gas Production
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- PRTG Energy
- ABP Health Care
- Exchange
- PRTG Nasdaq
- ABP Nasdaq
- Market Cap
- PRTG 17.7M
- ABP 15.5M
- IPO Year
- PRTG N/A
- ABP N/A
- Fundamental
- Price
- PRTG $5.69
- ABP $0.21
- Analyst Decision
- PRTG
- ABP Strong Buy
- Analyst Count
- PRTG 0
- ABP 1
- Target Price
- PRTG N/A
- ABP $4.00
- AVG Volume (30 Days)
- PRTG 234.2K
- ABP 5.6M
- Earning Date
- PRTG 08-26-2025
- ABP 08-18-2025
- Dividend Yield
- PRTG N/A
- ABP N/A
- EPS Growth
- PRTG N/A
- ABP N/A
- EPS
- PRTG N/A
- ABP N/A
- Revenue
- PRTG N/A
- ABP $183,000.00
- Revenue This Year
- PRTG N/A
- ABP N/A
- Revenue Next Year
- PRTG N/A
- ABP N/A
- P/E Ratio
- PRTG N/A
- ABP N/A
- Revenue Growth
- PRTG N/A
- ABP 88.66
- 52 Week Low
- PRTG $2.10
- ABP $0.15
- 52 Week High
- PRTG $23.01
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- PRTG 39.99
- ABP N/A
- Support Level
- PRTG $5.24
- ABP N/A
- Resistance Level
- PRTG $6.84
- ABP N/A
- Average True Range (ATR)
- PRTG 0.76
- ABP 0.00
- MACD
- PRTG -0.09
- ABP 0.00
- Stochastic Oscillator
- PRTG 18.10
- ABP 0.00
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.